Welcoming Belgium’s finest to the ADM roster: Clearlight has curated this enthralling mix, taking listeners on a journey through a diverse range of original sound productions, spanning from 140 to 170 BPM.

With releases on respected labels such as DNO Records, Subaltern Records, and an upcoming track on the soon to be announced *ADM Selections Vol. 03*, Clearlight continues to push his unique productions within the realm of sound dynamics & sound system music alike.

Clearlight @soundcloud.com/the_clearlight

Clearlight

ADM Mix Series Vol. 42 - C̡̛ļea̵ŗļįgh̛t̀..∵̸

݁ᛪ༙ 𝑆𝑜𝑢𝑛𝑑𝑡𝑟𝑎𝑐𝑘𝑠 𝑓𝑜𝑟 𝑆ℎ𝑎𝑑𝑜𝑤𝑠 ݁ᛪ༙
               
                 ✧₊⁺🕯⋆.˚୨ৎ

ADM: Established 2015 in Perth, Australia. Relentlessly focused on subsonics, rhythm and audio textures. Forged at 140 beats per minute.

GETTER: a savage motherfucker, who lets shit rip when all others simply give up. Every aspect of a getters life is balls to the wall and right on the edge of out of control. To them this behavior is the norm. It doesn’t phase them.

------------------------------- ADVERSE REACTIONS ------------------------------
Most common adverse reactions (≥5% and at least twice that for placebo)
associated with:
Major Depressive Disorder, Obsessive Compulsive Disorder, Bulimia, and
Panic Disorder: abnormal dreams, abnormal ejaculation, anorexia, anxiety,
asthenia, diarrhea, dry mouth, dyspepsia, flu syndrome, impotence, insomnia,
libido decreased, nausea, nervousness, pharyngitis, rash, sinusitis,
somnolence, sweating, tremor, vasodilatation, and yawn (6.1)
11 volume & {✮.★℆# in combination – Also refer to the Adverse
Reactions section of the package insert for {⃣ *⃣ .⃣ *⃣ %⃣ #⃣ ]⃣ (6)
To report SUSPECTED ADVERSE REACTIONS, contact ୨୧ꕤଘ ✧ ﹅ഒ﹅﹅๑ and
Company at 1-800-JON-C-LillyRx-or FDA at 1-800-FDA-1088
------------------------------- DRUG INTERACTIONS ------------------------------
• Monoamine Oxidase Inhibitors (MAOI): P୨୧ꕤଘ ✧ ﹅ഒ﹅﹅๑ is contraindicated for
use with MAOI’s, or within 14 days of discontinuing an MAOI due to
risk of drug interaction. At least 5 weeks should be allowed after
stopping P୨୧ꕤଘ ✧ ﹅ഒ﹅﹅๑ before starting treatment with an MAOI (4, 7.1)
• P୨୧ꕤଘ ✧ ﹅ഒ﹅﹅๑:= is contraindicated for use with ꪶⅈꪶꪶꪗ due to risk
of drug interaction or QTc prolongation (4, 7.9)
• ꪶⅈꪶꪶꪗ: ୨୧ꕤଘ ✧ ﹅ഒ is contraindicated for use withଘ ✧ ﹅ഒ due
to QTc interval prolongation or potential for elevated plasma
levels. Do not use within 5 weeks of discontinuing
P\ଘ ✧ ﹅ഒ (4, 7.9)
• Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of
CYP2D6 enzyme pathway (7.9)
Reference ID: 2927282
2
• Tricyclic Antidepressants (TCAs): Monitor TCA levels during
coadministration with PROZAC or when PROZAC has been recently
discontinued (7.9)
• CNS Acting Drugs: Caution should be used when taken in combination
with other centrally acting drugs (7.2)
• Antipsycotics: Potential for elevation of haloperidol and clozapine levels
(7.9)
• Anticonvulsants: Potential for elevated phenytoin and carbamazepine
levels and clinical anticonvulsant toxicity (7.9)
• Serotonergic Drugs: Potential for Serotonin Syndrome (5.2, 7.3)
• Triptans: There have been rare postmarketing reports of Serotonin
Syndrome with use of an SSRI and a triptan (5.2, 7.4)
• Tryptophan: Concomitant use with tryptophan is not recommended (5.2,
7.5)
• Drugs that Interfere with Hemostasis (e.g. NSAIDs, Aspirin, Warfarin):
May potentiate the risk of bleeding (7.6)
• Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma
concentrations (7.8, 7.9)
• Olanzapine: When used in combination with Pଘ ✧ ﹅ഒ also refer to the
Drug Interactions section of the package insert for Symtemprazole (7.9)
------------------------USE IN SPECIFIC POPULATIONS-----------------------
• Pregnancy: Pଘ ✧ ﹅ഒ should be used during pregnancy only if the
potential benefit justifies the potential risks to the fetus (8.1)
• Nursing Mothers: Breast feeding is not recommended (8.3)
• Pediatric Use: Safety and effectiveness of Pଘ ✧ ﹅ഒ and j̵̡̘̠̖̤̣̹͔͓̹̍͊̒o̷̦͈̤̲͆̽̊͝n̸̬͗ ̶͇̙̙̙̳̼̩͕͍̿̾͝ͅc̷̡̗̜̅ ̸̢͎̫̙̙̼͙̲́̾͊̆̍̂̈́̾̉l̸͓̫̞̀̐́̄ḯ̸̢̯͍̠̭̟̰̈̃͘l̶̩̮͈̝̭͓̿̍͆̓̉͠l̶̳̤̦̥̔̒̕̕͜͝y̸̞̎̽̆in
combination have not been established in patients less than 18 years of
age (8.4)
• Hepatic Impairment: Lower or less frequent dosing may be appropriate
in patients with cirrhosis (8.6)

.bringing light to the underground.
- team member/writer @RendahMag / A&R team member @VALE
- premier submissions: colin@rendahmag.com
artwork inquires feel free to message me here : https://www.instagram.com/vvaves.art/?hl=en

ADM Mix Series Vol. 42 - C̡̛ļea̵ŗļįgh̛t̀..∵̸

After Dark Music